Cyclophosphamide and alveolitis

New York, June 28, 2000 (Praxis Press) Interstitial lung disease is a major cause of death in patients with systemic sclerosis (scleroderma). Studies have not precisely evaluated the association between alveolitis and lung fibrosis, and the subsequent deterioration of pulmonary function.

June 28, 2000

New York, June 28, 2000 (Praxis Press) Interstitial lung disease is a major cause of death in patients with systemic sclerosis (scleroderma). Studies have not precisely evaluated the association between alveolitis and lung fibrosis, and the subsequent deterioration of pulmonary function. A recent retrospective cohort study compared the outcomes of three patient groups with scleroderma lung disease: patients without alveolitis, and alveolitis patients with and without cyclophosphamide treatment and determined that that scleroderma patients with alveolitis have a higher rate of lung deterioration and mortality than scleroderma patients without alveolitis (see paper). The study further determined that alveolitis patients following a cyclophosphamide treatment had improved lung function outcomes and longer survival rates. This study suggests that cyclophosphamide is an effective intervention in alveolitis patients, although the benefits of this medication still have to be confirmed by a randomized placebo-controlled clinical trial. Consider prescribing cyclophosphamide to scleroderma alveolitis patients.

Popular Now

  1. Top 10 Innovations 2016
    Features Top 10 Innovations 2016

    This year’s list of winners celebrates both large leaps and small (but important) steps in life science technology.

  2. Pubic Hair Grooming Linked to STI Risk
    The Nutshell Pubic Hair Grooming Linked to STI Risk

    Observational study suggests pubic hair grooming correlates with heightened risk of acquiring sexually transmitted infections, although causation remains unclear.

  3. Gut Microbes Linked to Neurodegenerative Disease
  4. Toward Treating Alzheimer’s Disease with Brain Waves
Rockland